Treatment of Hepatitis B in Decompensated Liver Cirrhosis | Zendy

Richard Guan | Zendy; Hock Foong Lui | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Hepatitis B in Decompensated Liver Cirrhosis

Author(s) -

Richard Guan,

Hock Foong Lui

Publication year - 2011

Publication title -

international journal of hepatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.734

H-Index - 14

eISSN - 2090-3448

pISSN - 2090-3456

DOI - 10.4061/2011/918017

Subject(s) - medicine , cirrhosis , hepatocellular carcinoma , entecavir , lamivudine , hepatitis b , gastroenterology , liver disease , hepatitis b virus , asymptomatic , viral hepatitis , virology , virus

Chronic hepatitis B infection progresses from an asymptomatic persistently infected state to chronic hepatitis, cirrhosis, decompensated liver disease, and/or hepatocellular carcinoma. About 3% of patients with chronic hepatitis develop cirrhosis yearly, and about 5% of individuals with hepatitis B cirrhosis become decompensated annually. The outcome for patients with decompensated cirrhosis is bleak. Lamivudine, the first oral antiviral agent available for hepatitis B treatment is safe and effective and can improve or stabilize liver disease in patients with advanced cirrhosis and viraemia. Viral resistance restricts its prolonged use. Entecavir and tenofovir are newer agents with excellent resistance profile to date. These and some other antiviral agents are being investigated for optimal use in this rather challenging patient group.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research